387 related articles for article (PubMed ID: 17612953)
1. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
Masubuchi Y; Horie T
Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
Hollenberg PF; Kent UM; Bumpus NN
Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
[TBL] [Abstract][Full Text] [Related]
3. cDNA-expressed human cytochrome P450 isozymes. Inactivation by porphyrinogenic xenobiotics.
McNamee JP; Jurima-Romet M; Kobus SM; Marks GS
Drug Metab Dispos; 1997 Apr; 25(4):437-41. PubMed ID: 9107543
[TBL] [Abstract][Full Text] [Related]
4. Isolation of regioisomers of N-alkylprotoporphyrin IX from chick embryo liver after treatment with porphyrinogenic xenobiotics.
Kobus SM; Wong SG; Marks GS
Can J Physiol Pharmacol; 2001 Sep; 79(9):814-21. PubMed ID: 11599783
[TBL] [Abstract][Full Text] [Related]
5. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
6. Isolation of N-vinylprotoporphyrin IX after hepatic cytochrome P450 inactivation by 3-[(arylthio)ethyl]sydnone in chick embryos pretreated with phenobarbital, glutethimide, dexamethasone, and beta-naphthoflavone: differential inhibition of ferrochelatase by N-vinylprotoporphyrin regioisomers.
Kimmett SM; Whitney RA; Marks GS
Mol Pharmacol; 1996 Apr; 49(4):676-82. PubMed ID: 8609896
[TBL] [Abstract][Full Text] [Related]
7. Short-term inhibitory effects of nitric oxide on cytochrome P450-mediated drug metabolism: time dependency and reversibility profiles in isolated perfused rat livers.
Vuppugalla R; Mehvar R
Drug Metab Dispos; 2004 Dec; 32(12):1446-54. PubMed ID: 15383494
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
Alvarez-Diez TM; Zheng J
Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?
Blobaum AL
Drug Metab Dispos; 2006 Jan; 34(1):1-7. PubMed ID: 16369051
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.
Venkatakrishnan K; Obach RS; Rostami-Hodjegan A
Xenobiotica; 2007; 37(10-11):1225-56. PubMed ID: 17968744
[TBL] [Abstract][Full Text] [Related]
11. 1,2,3-Thiadiazole: a novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors.
Babu BR; Vaz AD
Biochemistry; 1997 Jun; 36(23):7209-16. PubMed ID: 9188722
[TBL] [Abstract][Full Text] [Related]
12. Drug metabolism by cytochromes P450 in the liver and small bowel.
Watkins PB
Gastroenterol Clin North Am; 1992 Sep; 21(3):511-26. PubMed ID: 1516957
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 and its interactions with the heme biosynthetic pathway.
De Matteis F; Marks GS
Can J Physiol Pharmacol; 1996 Jan; 74(1):1-8. PubMed ID: 8963944
[TBL] [Abstract][Full Text] [Related]
14. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies.
Bourdi M; Tinel M; Beaune PH; Pessayre D
Mol Pharmacol; 1994 Jun; 45(6):1287-95. PubMed ID: 8022422
[TBL] [Abstract][Full Text] [Related]
15. A basic conceptual and practical overview of interactions with highly prescribed drugs.
Dresser GK; Bailey DG
Can J Clin Pharmacol; 2002; 9(4):191-8. PubMed ID: 12584577
[TBL] [Abstract][Full Text] [Related]
16. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
Bachmann KA; Lewis JD
Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
[TBL] [Abstract][Full Text] [Related]
17. Designing better drugs: predicting cytochrome P450 metabolism.
de Groot MJ
Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
[TBL] [Abstract][Full Text] [Related]
18. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K
Drug Metab Dispos; 2007 Feb; 35(2):246-55. PubMed ID: 17093004
[TBL] [Abstract][Full Text] [Related]
19. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
McGinnity DF; Waters NJ; Tucker J; Riley RJ
Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
[TBL] [Abstract][Full Text] [Related]
20. The human hepatic cytochromes P450 involved in drug metabolism.
Wrighton SA; Stevens JC
Crit Rev Toxicol; 1992; 22(1):1-21. PubMed ID: 1616599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
